

ERS Research Seminar

***Pharmacology of asthma and COPD: current and future developments***

*10 – 11 June 2021; Napoli, Italy*

**Day 1 – Thursday, 10 June 2020**

08:45-09:00 Registration

09:00-09:10 Welcome and introduction

**Session 1: Pharmacology of asthma and COPD - current knowledge**

09:10-09:30 Understanding the mechanism of action of bronchodilators in asthma and COPD

09:30-09:40 Discussion

09:40-10:00 How do inhaled steroids work and interact in asthma and COPD?

10:00-10:10 Discussion

10:10-10:30 Biomarker guided pharmacological intervention

10:30-10:40 Discussion

10:40-11:10 General discussion

*11:10-11:30 Coffee break*

**Session 2: Challenges for clinical development**

11:30-12:00 Key challenges faced during clinical development of anti-inflammatory drugs for asthma and COPD

12:00-12:30 General discussion

*12:30-13:30 Lunch*

**Session 3: Emerging new concepts and treatments**

13:30-13:50 Do we understand remodeling in asthma and COPD?

13:50-14:00 Discussion

14:00-14:20 Lung regeneration: is it still far from reality?

14:20-14:30 Discussion

14:30-14:50 Emerging classes of drugs for the treatment of obstructive lung disease

14:50-15:00 Discussion

**15:00-17:30 Session 4 – Breakout: what is this seminar's position on the selection of treatment in asthma and COPD?**

15:00-15:15 Explain tasks and operating methods

**15:30-16:15 Session 1 - Identifying surrogate markers and outcomes**

- Which surrogate markers can be used to assess and quantify disease in a pre-clinical stage? Do we need drug intervention in pre-clinical detectable disease?

- Which are the read-outs to assess drug effect in the progression of the disease?
- Is an effect on remodeling required for drug efficacy? If so, how to assess it?

**16:15-17:00 Session 2 - How do we select treatments for patients with severe asthma and COPD?**

- What is non-clinical evidence to sustain combination therapy including ICS in COPD? What about LABA/LAMA in asthma?
- Are there realistic treatment goals for monoclonal antibodies in COPD? How do they differ from asthma?
- Which features suggest considering patients for non-pharmacological, i.e. bronchoscopic interventions in asthma and COPD?

**17:00-17:30 Round table**

**Day 2 – Friday, 11 June 2020**

09:00-09:30 Summary of day 1 and possible output, next steps and plenary discussion

**Session 5: Challenges in the treatment of patient with asthma and COPD**

09:30-09:50 New insights into steroid resistance

09:50-10:00 Discussion

10:00-10:20 Comorbidities and drug interactions

10:20-10:30 Discussion

10:30-10:50 Pharmacogenetics of asthma and COPD and treatment

10:50-11:00 Discussion

11:00-11:20 General discussion

**11:20-11:40 Coffee break**

**11:40-12:20 Session 6 – Breakout: what is this seminar’s position on the selection of treatment in asthma and COPD?**

11:40-11:50 Explain tasks and operating methods

**11:50-12:20 Session 1 - How to streamline clinical and basic research**

- How to translate relevant clinical questions to experiments?
- How to translate experimental data to clinical practice?
- Which themes should be prioritized?
- How can academia and industry cooperate?

**12:20-12:50 Round table**

12:50-13:00 Conclusion

**13:00-14:00 Lunch and Departure**